一项关于环磷酰胺和顺铂联合或不联合阿霉素治疗晚期卵巢癌的随机研究。
A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma.
作者信息
Bertelsen K, Jakobsen A, Andersen J E, Ahrons S, Pedersen P H, Kiaer H, Arffmann E, Bichel P, Boestofte E, Strøyer I
机构信息
Danish Ovarian Cancer Group, Department of Oncology, University Hospital, Odense, Denmark.
出版信息
Gynecol Oncol. 1987 Oct;28(2):161-9. doi: 10.1016/0090-8258(87)90210-1.
Two hundred sixty-seven patients with advanced epithelial ovarian carcinoma were randomized to cis-platinum and cyclophosphamide versus cis-platinum, cyclophosphamide, and doxorubicin. Complete pathological response, evaluated at second-look laparotomy and survival, showed no differences between the two treatment groups. Recurrence-free survival after negative second look was 61% at 24 months.
267例晚期上皮性卵巢癌患者被随机分为顺铂和环磷酰胺组与顺铂、环磷酰胺及阿霉素组。在二次剖腹探查时评估的完全病理缓解情况及生存率显示，两个治疗组之间无差异。二次探查结果为阴性后的无复发生存率在24个月时为61%。
Zotero 插件